NCT03078387 is a clinical trial of imaging in Life Threatening Diseases, sponsored by Dr. Shawkat Michel.

Who is sponsoring NCT03078387?

NCT03078387 is sponsored by Dr. Shawkat Michel.

What drugs are being tested in NCT03078387?

Interventions in NCT03078387: imaging.

What condition does NCT03078387 study?

NCT03078387 studies Life Threatening Diseases, Embolic Shower.

Is NCT03078387 still recruiting?

NCT03078387 is currently completed. Last updated 4 April 2019.

Last reviewed 2019-04-04 · How we verify

NCT03078387

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Extreme Significance of Bilateral Embolic Retinal Phenomena That Can be Life Saving

Completed Last updated 4 April 2019

What this trial tests

trial testing imaging in Life Threatening Diseases in 2 participants. Completed in 31 December 2018.

Timeline

31 August 2006

Primary endpoint
29 January 2013

31 December 2018

Quick facts

Lead sponsor	Dr. Shawkat Michel
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2
Start date	31 August 2006
Primary completion	29 January 2013
Estimated completion	31 December 2018
Sites	1 location across Canada

Drugs / interventions tested

imaging

Conditions studied

Life Threatening Diseases — all drugs for Life Threatening Diseases →
Embolic Shower — all drugs for Embolic Shower →

Sponsor

Dr. Shawkat Michel

Who can join

Adults 30 to 80, any sex, with Life Threatening Diseases or Embolic Shower. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study shows how careful ophthalmic examination of two patients showed signs of simultaneous bilateral retinal emboli. Starting from this point significant, life threatening, underlying reasons were found and treated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of imaging

Trials testing the same drug.

NCT07056738 — Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients · enrolling by invitation
NCT06718608 — Natural Evolution of Muscle Structure and Stiffness Following Brain Lesion · NA · not yet recruiting
NCT06286267 — AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors · recruiting
NCT04976998 — Role of Ultrasonography in the Diagnosis of Carpal Tunnel Syndrome · unknown
NCT05902650 — Correlation of Biochemical Indexes and Retinal Hemodynamic in Patients With Different Degrees of Diabetic Retinopathy · unknown

Other recruiting trials for Life Threatening Diseases

Currently open trials in the same condition.

NCT06915883 — Experiential and Relaxation Virtual Reality as a Tool for Easing Anxiety in Seriously Ill Children · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03078387 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr. Shawkat Michel
Last refreshed: 4 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03078387.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing